Volition launches its nu.q® vet cancer test in asia through its appointed distributor sage healthcare

Austin, texas , april 25, 2022 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering diseases in both humans and animals, has announced the launch of its nu.q ® vet cancer test in asia through its appointed distributor sage healthcare private limited. as previously announced, sage was appointed in december 2021 to serve as a non-exclusive licensee and distributor for volition's nu.q® vet cancer test in centralized labs in singapore.
VNRX Ratings Summary
VNRX Quant Ranking